SG10201600077RA - Combination - Google Patents
CombinationInfo
- Publication number
- SG10201600077RA SG10201600077RA SG10201600077RA SG10201600077RA SG10201600077RA SG 10201600077R A SG10201600077R A SG 10201600077RA SG 10201600077R A SG10201600077R A SG 10201600077RA SG 10201600077R A SG10201600077R A SG 10201600077RA SG 10201600077R A SG10201600077R A SG 10201600077RA
- Authority
- SG
- Singapore
- Prior art keywords
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161431508P | 2011-01-11 | 2011-01-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201600077RA true SG10201600077RA (en) | 2016-02-26 |
Family
ID=46507420
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201600077RA SG10201600077RA (en) | 2011-01-11 | 2012-01-11 | Combination |
| SG2013043856A SG191724A1 (en) | 2011-01-11 | 2012-01-11 | Combination |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013043856A SG191724A1 (en) | 2011-01-11 | 2012-01-11 | Combination |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US20130288984A1 (en) |
| EP (1) | EP2663189B1 (en) |
| JP (1) | JP6100700B2 (en) |
| KR (1) | KR20140053836A (en) |
| CN (1) | CN103298345B (en) |
| AU (1) | AU2012205601B2 (en) |
| BR (1) | BR112013017722A2 (en) |
| CA (1) | CA2824201A1 (en) |
| EA (1) | EA029000B1 (en) |
| ES (1) | ES2689760T3 (en) |
| IL (1) | IL227097B (en) |
| MX (1) | MX356704B (en) |
| SG (2) | SG10201600077RA (en) |
| WO (1) | WO2012097021A1 (en) |
| ZA (1) | ZA201304139B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2925374A1 (en) * | 2013-10-01 | 2015-04-09 | Novartis Ag | Combination |
| JP6568093B2 (en) * | 2013-11-07 | 2019-08-28 | デシフェラ ファーマシューティカルズ，エルエルシー | Method of inhibiting TIE2 kinase useful for cancer treatment |
| WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| MX2022001863A (en) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Ripretinib for treating gastrointestinal stromal tumors. |
| MX2022008103A (en) | 2019-12-30 | 2022-09-19 | Deciphera Pharmaceuticals Llc | Amorphous kinase inhibitor formulations and methods of use thereof. |
| KR20220123058A (en) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-Bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl ) -3-Phenylurea composition |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6328590B1 (en) | 2000-07-20 | 2001-12-11 | Emc Corporation | Methods and apparatus for controlling attachment of an electronic module with a circuit board connector |
| US7468371B2 (en) * | 2004-03-24 | 2008-12-23 | Abbott Laboratories Inc. | Tricyclic pyrazole kinase inhibitors |
| EP2708531A1 (en) | 2004-10-13 | 2014-03-19 | Pharmacia & Upjohn Company LLC | Crystalline Forms Of 3-[5-Chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| EP1928437A2 (en) * | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP1840114A1 (en) | 2006-03-30 | 2007-10-03 | LTB4 Sweden AB | Crystalline Leukotriene B4 |
| EP2004165A2 (en) | 2006-04-05 | 2008-12-24 | Novartis Pharma AG | Synergistic combinations of anticancer agents for treating cancer |
| WO2007122686A1 (en) | 2006-04-14 | 2007-11-01 | Eisai R & D Management Co., Ltd. | Benzimidazole compounds |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| ES2428634T3 (en) | 2006-08-25 | 2013-11-08 | Janssen Oncology, Inc. | Compositions for cancer treatment |
| JP4299327B2 (en) | 2006-08-31 | 2009-07-22 | トヨタ自動車株式会社 | Variable valve timing device |
| US8828451B2 (en) | 2006-10-04 | 2014-09-09 | University Of South Florida | Akt sensitization of cancer cells |
| EP2079714B1 (en) | 2006-10-13 | 2012-09-26 | Basf Se | Hydrates of 2-chloro-5-ý3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoro-methyl)-1-(2h)-pyrimidinyl¨-4-fluoro-n-ýýmethyl-(1-methylethyl)-amino¨sulphonyl¨benzamide |
| AR064010A1 (en) * | 2006-12-06 | 2009-03-04 | Merck & Co Inc | AKT ACTIVITY INHIBITORS |
| UY30892A1 (en) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | AKT ACTIVITY INHIBITORS |
| KR101494734B1 (en) | 2007-10-11 | 2015-02-26 | 아스트라제네카 아베 | Pyrrolo[ 2,3-d] pyrimidin derivatives as protein kinase b inhibitors |
| US20090131367A1 (en) * | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
| DE102008044901A1 (en) | 2008-08-29 | 2010-03-04 | Siemens Aktiengesellschaft | Method and device for selecting an irradiation plan and irradiation facility |
| PE20120003A1 (en) | 2009-01-30 | 2012-02-12 | Glaxosmithkline Llc | N - {(1S) -2-AMINO-1 - [(3-FLUOROPHENYL) METHYL) ETHYL HYDROCHLORIDE} -5-CHLORO-4- (4-CHLORO-1-METHYL-1H-PIRAZOL-5-IL) - CRYSTALLINE 2-THIOPHENOCARBOXAMIDE |
| SG176105A1 (en) | 2009-06-26 | 2011-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| ES2530436T3 (en) | 2009-10-08 | 2015-03-02 | Glaxosmithkline Llc | Combination |
| ES2657750T3 (en) | 2011-04-01 | 2018-03-06 | Genentech, Inc. | Combination of AKT inhibitor compound and vemurafenib for use in therapeutic treatments |
| EP2704699A1 (en) | 2011-05-03 | 2014-03-12 | University of Rochester | Methods for treating prostate cancer |
| KR20140048968A (en) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | Inhibitors of bruton's tyrosine kinase |
| WO2013053691A1 (en) | 2011-10-10 | 2013-04-18 | Zach System | Process for preparing 17-substituted steroids |
| LT2785349T (en) | 2011-11-30 | 2019-12-10 | Astrazeneca Ab | Combination treatment of cancer |
| KR20220093389A (en) | 2012-06-04 | 2022-07-05 | 파마싸이클릭스 엘엘씨 | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| JP6355724B2 (en) | 2013-10-01 | 2018-07-11 | ノバルティス アーゲー | Enzalutamide in combination with afreseltiv to treat cancer |
-
2012
- 2012-01-11 WO PCT/US2012/020863 patent/WO2012097021A1/en active Application Filing
- 2012-01-11 MX MX2013008074A patent/MX356704B/en active IP Right Grant
- 2012-01-11 SG SG10201600077RA patent/SG10201600077RA/en unknown
- 2012-01-11 KR KR1020137021098A patent/KR20140053836A/en active IP Right Grant
- 2012-01-11 SG SG2013043856A patent/SG191724A1/en unknown
- 2012-01-11 CN CN201280004830.0A patent/CN103298345B/en active Active
- 2012-01-11 ES ES12733916.6T patent/ES2689760T3/en active Active
- 2012-01-11 CA CA2824201A patent/CA2824201A1/en not_active Abandoned
- 2012-01-11 JP JP2013549503A patent/JP6100700B2/en active Active
- 2012-01-11 AU AU2012205601A patent/AU2012205601B2/en not_active Ceased
- 2012-01-11 EA EA201391027A patent/EA029000B1/en not_active IP Right Cessation
- 2012-01-11 BR BR112013017722A patent/BR112013017722A2/en not_active IP Right Cessation
- 2012-01-11 US US13/978,765 patent/US20130288984A1/en not_active Abandoned
- 2012-01-11 EP EP12733916.6A patent/EP2663189B1/en active Active
- 2012-02-08 US US13/368,434 patent/US20120258933A1/en not_active Abandoned
-
2013
- 2013-06-06 ZA ZA2013/04139A patent/ZA201304139B/en unknown
- 2013-06-20 IL IL227097A patent/IL227097B/en active IP Right Grant
-
2015
- 2015-01-06 US US14/590,143 patent/US20150119337A1/en not_active Abandoned
- 2015-08-20 US US14/831,261 patent/US20160022641A1/en not_active Abandoned
-
2016
- 2016-09-08 US US15/259,694 patent/US20160375086A1/en not_active Abandoned
- 2016-12-20 US US15/385,205 patent/US10449226B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10449226B2 (en) | 2019-10-22 |
| WO2012097021A1 (en) | 2012-07-19 |
| CN103298345B (en) | 2016-12-14 |
| SG191724A1 (en) | 2013-08-30 |
| EP2663189B1 (en) | 2018-07-04 |
| US20150119337A1 (en) | 2015-04-30 |
| MX356704B (en) | 2018-06-11 |
| ZA201304139B (en) | 2014-02-26 |
| MX2013008074A (en) | 2013-08-09 |
| US20120258933A1 (en) | 2012-10-11 |
| EP2663189A4 (en) | 2014-06-11 |
| AU2012205601B2 (en) | 2016-03-24 |
| US20130288984A1 (en) | 2013-10-31 |
| EP2663189A1 (en) | 2013-11-20 |
| ES2689760T3 (en) | 2018-11-15 |
| CN103298345A (en) | 2013-09-11 |
| IL227097B (en) | 2018-02-28 |
| AU2012205601A1 (en) | 2013-08-01 |
| JP2014507412A (en) | 2014-03-27 |
| JP6100700B2 (en) | 2017-03-22 |
| US20170100449A1 (en) | 2017-04-13 |
| US20160375086A1 (en) | 2016-12-29 |
| US20160022641A1 (en) | 2016-01-28 |
| EA201391027A1 (en) | 2014-01-30 |
| BR112013017722A2 (en) | 2016-07-12 |
| KR20140053836A (en) | 2014-05-08 |
| EA029000B1 (en) | 2018-01-31 |
| CA2824201A1 (en) | 2012-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3798230T3 (en) | Terapeutiske antistoffer | |
| EP2790561A4 (en) | Dishmachine | |
| EP2755962A4 (en) | Azaindazoles | |
| EP2715659A4 (en) | Überfeed | |
| EP2776444A4 (en) | Dihydropteridinones | |
| EP2723631A4 (en) | Quadfolier | |
| AP2014007621A0 (en) | 2-Thiopyrimidinones | |
| ZA201304866B (en) | Colonoscopy-preparation | |
| EP2695208A4 (en) | Micro-thermocouple | |
| ZA201304139B (en) | Combination | |
| PL2606715T3 (en) | Baler-wrapper combination | |
| EP2679138A4 (en) | Endsoscope | |
| SG10201606981QA (en) | 18f-saccharide-folates | |
| DK2770906T3 (en) | Applanationstonometer | |
| EP2684382A4 (en) | Earpuff | |
| EP2698098A4 (en) | Campimeter | |
| EP2694655A4 (en) | pAVEC | |
| EP2672969A4 (en) | Combination | |
| GB201101727D0 (en) | Obuoy | |
| GB201100001D0 (en) | TidySqueeze2 | |
| AU4540P (en) | BUNNAN Baloskion tetraphyllum | |
| AU5171P (en) | Sunparamiho Mandevilla xamabilis | |
| AU5031P (en) | BESYS Beschorneria yuccoides | |
| AU5026P (en) | Goldstrike Agapanthus inapertus | |
| GB201121105D0 (en) | Combination |